Quick Answer
Indivior Pharmaceuticals, Inc. reported Gross Profit of $994.00 million for fiscal year 2025.
Indivior Pharmaceuticals, Inc. Gross Profit — Annual History
| Fiscal Year | Gross Profit | YoY Change |
|---|---|---|
| 2025 | $994.00M | +3.9% |
| 2024 | $957.00M | +4.1% |
| 2023 | $919.00M | +22.7% |
| 2022 | $749.00M | +12.8% |
| 2021 | $664.00M | — |
Quarterly Gross Profit
| Quarter Ending | Gross Profit | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | $230.00M | -4.6% | -8.0% |
| June 30, 2025 | $250.00M | +13.6% | +13.1% |
| March 31, 2025 | $221.00M | -10.2% | -8.3% |
| September 30, 2024 | $241.00M | — | +9.5% |
| June 30, 2024 | $220.00M | — | -10.6% |
| March 31, 2024 | $246.00M | — | — |
- Indivior Pharmaceuticals, Inc. showed an increase of +3.9% in Gross Profit compared to the prior fiscal year.
- Over the 2021–2025 period, Indivior Pharmaceuticals, Inc.’s gross profit has grown by 49.7% (from $664.00 million to $994.00 million).
- The most recent figure is from Indivior Pharmaceuticals, Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on February 26, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: